The insider sales are too small to warrant a bearish read-through. Monitor the XOMA acquisition closing (Q3 2026) and upcoming quarterly filings for any change in insider selling patterns. The strong Q1 royalty growth and raised guidance support the current bullish analyst consensus (93% buy).
LGND drugs
LGND drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $227.44entry
- T+1 · 7mo ago +0.40%α +0.75% · $228.36
- T+5 · 6mo ago −2.65%α −5.00% · $221.41
- T+20 · 6mo ago +1.03%α −4.26% · $229.78
- T+60 · 4mo ago +30.27%α +27.20% · $296.28
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director John Kozarich and CLO Andrew Reardon sold a combined $155K in open-market sales on May 1, 2026, following Ligand's strong Q1 earnings (royalty revenue +56% YoY) and the reaffirmation of raised 2026 guidance tied to the pending XOMA acquisition. The sales are small relative to the $4.4B market cap (0.0035%) and likely reflect routine portfolio rebalancing or tax planning, not a bearish signal on fundamentals.
Key Financial Metrics
Key Facts
- Two insiders sold a total of 680 shares for $155K on May 1, 2026.
- Sales represent ~0.0035% of Ligand's $4.4B market cap, trivial in size.
- Director Kozarich also exercised and sold shares on May 12-13, 2026, in a separate cluster ($455K total).
- Q1 2026 earnings showed royalty revenue up 56% YoY to $43M; adjusted EPS of $1.63 beat prior year's $1.33.
- Ligand reaffirmed raised 2026 guidance: adjusted EPS $8.50-$9.50, royalty revenue $225M-$250M.
- Pending XOMA acquisition ($39/share cash + CVR) expected to close in Q3 2026.
Financial Impact
Insider sales of $155K are immaterial relative to $4.4B market cap.
Risk Factors
- Pending XOMA acquisition may face stockholder approval or regulatory delays.
- Captisol sales declined 36% YoY in Q1 2026 due to customer order timing.
- Non-cash loss on Pelthos investment ($49.2M) drove GAAP net loss of $13.3M.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-LGND-1778807348557 |
Track record
29 reports on LGND
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers